Gramax Health Bhd (GHB), a company operates in a health industry, is working in a project to develop a test kit that is able to determine the level of immunity a person has towards Covid- 19 based on his or her antibodies with higher accuracy rate compared with other similar test kits that are available in the market. In a recent business combination, GHB acquires a research and development (R&D) project of Vital Life Bhd (VLB) to develop a similar test kit with the one it develops. GHB does not intend to complete the project that had been acquired as it would compete with its own project. Its main intention to acquire the project is to prevent its competitors from obtaining access to the technology. Meanwhile, as part of its effort to fund its R&D projects, on 31 December 2019 GHB issued at par in a private placement a RM3 million 5-year fixed rate bond with an annual 10% interest coupon rate. On 31 December 2020, GHB's credit spread has deteriorated due to a change in its non-performance risk If the bond was issued on 31 December 2020, the instrument would need to have an interest rate of 11%. In reducing its reliance on third party service, GHB also

Gramax Health Bhd (GHB), a company operates in a health industry, is working in a project to develop a test kit that is able to determine the level of immunity a person has towards Covid- 19 based on his or her antibodies with higher accuracy rate compared with other similar test kits that are available in the market. In a recent business combination, GHB acquires a research and development (R&D) project of Vital Life Bhd (VLB) to develop a similar test kit with the one it develops. GHB does not intend to complete the project that had been acquired as it would compete with its own project. Its main intention to acquire the project is to prevent its competitors from obtaining access to the technology. Meanwhile, as part of its effort to fund its R&D projects, on 31 December 2019 GHB issued at par in a private placement a RM3 million 5-year fixed rate bond with an annual 10% interest coupon rate. On 31 December 2020, GHB's credit spread has deteriorated due to a change in its non-performance risk If the bond was issued on 31 December 2020, the instrument would need to have an interest rate of 11%. In reducing its reliance on third party service, GHB also

FINANCIAL ACCOUNTING

10th Edition

ISBN:9781259964947

Author:Libby

Publisher:Libby

Chapter1: Financial Statements And Business Decisions

Section: Chapter Questions

Problem 1Q

See similar textbooks

Similar questions

Khair Ltd carries out research and development on a continuousbasis. The directors of the company are passionate aboutimproving their medicinal drugs and finding new cures.In the current financial year, the company has been makingsignificant findings regarding a vaccine for the coronavirus. To thiseffect, they have registered a patent for a new vaccine that willsoon be available to customers. The following costs have beenincurred in respect of the patent in the current financial year.Research salaries R250 000Development salaries R450 000Initial marketing costs R30 000Fees to register patent R78 000Materials used in development R12 000The development was completed on 1 July 2020.Patents are amortised on a straight‐line basis at 20% per annumwith no residual value.Prepare the journal entry to recognise the patent in the financialstatements of Khair Ltd on 1 July 2020.Narrations are required
Rachel Duncan is the CEO of Dyad Pharmaceuticals, and she faces a decision about her company's newest and most promising drug candidate: NZT-48. Clinical trials have been completed, and the team awaits an approval decision from the U.S. Food and Drug Administration (FDA) before it can be marketed. In the meantime, Ms. Duncan receives an offer from a global biotech company, International Genetics Incorporated (InGen) to license NZT-48 from Dyad. (Licensing here means that InGen provides capital to help the development and launch process of the new drug, but will share the profits with Dyad once the drug enters the market.) With InGen's offer, Ms. Duncan has a decision to make right now, before the FDA's decision. She can accept InGen's offer. If FDA approves the new drug, then Ms. Duncan estimates that her company's valuation will reach $3 billion; if FDA does not approve, with InGen's injected capital, Ms. Duncan estimates that her company would still value at $1 billion. If Ms. Duncan…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Humanics Ltd is considering a proposed investment to manufacture medical equipment for a large-scale international research project in the area of immunology. A new study found linking particular genes with particular traits may be used to find drug targets and may ultimately lead to new therapies to treat different autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Addison’s disease, multiple sclerosis, type 1 diabetes etc.). Such diseases are gaining ground and already affect millions of people around the world, so the outcome of the intended research could have a large application for future immunotherapy. An initial feasibility study cost $125,000 and showed that the project requires an initial investment of $18 million, which includes $2 million of new working capital necessary for production. The annual free cash flow is estimated to be $5.5 million for 10 years, the envisioned length of the research study at which time working capital will be recovered. The…
Clonal, Inc., a biotechnology company, developed and patented a diagnostic product called Trouver. Clonal purchased some research equipment to be used exclusively for Trouver and subsequent research projects. Clonaldefeated a legal challenge to its Trouver patent, and began production and marketing operations for the project.Corporate headquarters’ costs were allocated to Clonal’s research division as a percentage of the division’ssalaries.Required:1. How should the equipment purchased for Trouver be reported in Clonal’s income statements and statementsof financial position?2. a. Describe the accounting treatment of research and development costs
Al Omani, an SAOC company based in Muscat specializing in the manufacture and distribution equipment for disabled people, and their major clients are ministry of health and various private hospitals in Oman. Currently the company is evaluating a new capital expenditure project. In a joint venture with a German based company, it has developed a remote controlled pushchair, one of the first of its kind on the market. It has been unable to obtain a patent for the invention, but the management is sure that it will capture the market for the first three years. However year 4 and 5 it expects to be faced with firm competition. The details are set out below. (1) The project has an immediate cost of 2, 100, 000 . () Sales are expected to be RO.1,550,000 per annum for years 1 to 3, falling to RO.650,000 per annum for the two years after that No further sales of the product are expected after the end of this five-year period. (3) Cost of sales is 40% of sales. (4) Distribution costs represent…
Clonal Inc., a biotechnology company, developed and patented a diagnostic product called Trouver. Clonal purchased some research equipment to be used exclusively for Trouver and other research equipment to be used on Trouver and subsequent research projects. Clonal defeated a legal challenge to its Trouver patent and began production and marketing operations for the product. Clonal allocated its corporate headquarters’ costs to its research division as a percentage of the division’s salaries. Required: What is the definition of research and of development as defined by GAAP? Briefly indicate the justification for the existing GAAP relating to R&D costs. Explain how Clonal should report the equipment purchased for Trouver on its income statements and balance sheets. Explain how Clonal should report the legal costs incurred in defending Trouver’s patent on its statement of cash flows. Explain how Clonal should classify its corporate headquarters’ costs allocated to the…
As a distributor, SH Bhd has to make sure that healthcare provider prescribes gets to the right hospital, pharmacy or other healthcare facility safely, securely and reliably. Thus, for the past 10 months, SH Bhd has been conducting a research in developing a revolutionary new system to enhance the efficiency of its existing distribution system. SH Bhd believes this project will be a successful one and there are a few distributors companies who also show their interest to buy this system. The cost to patent this system when its ready is estimated at RM70,000. So far, SH Bhd has incurred RM175,000 to finance this project. However, as of company's year-end (December 31), this new system has not been marketed. This is due to an error which requires substantial amount of work by the researchers to fix the problem REQUIRED: Explain the accounting treatment for the cost incurred by SH Bhd to develop new distribution system in accordance to MFRS 138 Intangible Assets. Prepare the journal entry…
Clonal Inc., a biotechnology company, developed and patented a diagnostic product called Trouver. Clonal purchased some research equipment to be used exclusively for Trouver and other research equipment to be used on Trouver and subsequent research projects. Clonal defeated a legal challenge to its Trouver patent and began production and marketing operations for the product. Clonal allocated its corporate headquarters’ costs to its research division as a percentage of the division’s salaries. Required: 1. Explain how Clonal should report the equipment purchased for Trouver on its income statements and balance sheets. 2. Describe the accounting treatment of R&D costs. What is the justification for the accounting treatment of R&D costs? 3. Explain how Clonal should classify its corporate headquarters’ costs allocated to the research division on its income statement. 4. Explain how Clonal should report the legal costs incurred in defending Trouver’s patent on its statement of cash…